Cite
Thyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves’ Disease Change Differently According to the Type of Definitive Therapy Administered
MLA
Ulla Feldt-Rasmussen. “Thyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves’ Disease Change Differently According to the Type of Definitive Therapy Administered.” Clinical Thyroidology, vol. 33, Aug. 2021, pp. 350–53. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d93e26b8c14c5f9632d481eef5f48007&authtype=sso&custid=ns315887.
APA
Ulla Feldt-Rasmussen. (2021). Thyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves’ Disease Change Differently According to the Type of Definitive Therapy Administered. Clinical Thyroidology, 33, 350–353.
Chicago
Ulla Feldt-Rasmussen. 2021. “Thyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves’ Disease Change Differently According to the Type of Definitive Therapy Administered.” Clinical Thyroidology 33 (August): 350–53. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d93e26b8c14c5f9632d481eef5f48007&authtype=sso&custid=ns315887.